Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
株式のランク #7141
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
株価
$40.39
最終同期: 2023-08-18
時価総額
$1.70B
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Chinook Therapeutics, Inc. (KDNY)

カテゴリー

Chinook Therapeutics, Inc.(KDNY)の株式分割履歴
Chinook Therapeutics, Inc.株(シンボル:KDNY)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 28, 2026に行われました。
Aug 28, 2026より前に購入されたKDNY株は、現在0KDNY株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH